Vera Therapeutics, Inc. Operating Cash Flow
Vera Therapeutics, Inc. (VERA) reported Operating Cash Flow of -$206.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- Vera Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$100.25M.
- Vera Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$106.50M.
- Vera Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$69.99M.
- Vera Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$61.91M.
- Vera Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$241.10M.
- Vera Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$134.68M.
- Vera Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$92.18M.
- Vera Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$67.60M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$100.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$206.75M 10-Q · filed 2026-08-10 | -$276.75M derived: sum of 3 quarters · filed 2026-08-10 | -$338.65M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$106.50M 10-Q · filed 2026-05-07 | -$176.49M derived: sum of 2 quarters · filed 2026-05-07 | -$238.40M derived: sum of 3 quarters · filed 2026-05-07 | -$293.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$69.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$131.90M derived: sum of 2 quarters · filed 2026-02-26 | -$186.70M derived: sum of 3 quarters · filed 2026-08-10 | -$241.10M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$61.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$116.70M derived: sum of 2 quarters · filed 2026-08-10 | -$171.11M 10-Q · filed 2025-11-05 | -$210.29M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$54.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$109.20M 10-Q · filed 2026-08-10 | -$148.39M derived: sum of 3 quarters · filed 2026-08-10 | -$185.27M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$54.41M 10-Q · filed 2026-05-07 | -$93.59M derived: sum of 2 quarters · filed 2026-05-07 | -$130.47M derived: sum of 3 quarters · filed 2026-05-07 | -$155.25M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$39.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$76.07M derived: sum of 2 quarters · filed 2026-02-26 | -$100.85M derived: sum of 3 quarters · filed 2026-02-26 | -$134.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$36.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$61.67M derived: sum of 2 quarters · filed 2025-11-05 | -$95.50M 10-Q · filed 2025-11-05 | -$120.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$24.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$58.61M 10-Q · filed 2025-08-05 | -$83.76M derived: sum of 3 quarters · filed 2026-02-26 | -$106.73M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$33.83M 10-Q · filed 2025-05-07 | -$58.97M derived: sum of 2 quarters · filed 2026-02-26 | -$81.95M derived: sum of 3 quarters · filed 2026-02-26 | -$99.72M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$25.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$48.12M derived: sum of 2 quarters · filed 2026-02-26 | -$65.89M derived: sum of 3 quarters · filed 2026-02-26 | -$92.18M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$22.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$40.74M derived: sum of 2 quarters · filed 2024-11-07 | -$67.04M 10-Q · filed 2024-11-07 | -$88.20M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$17.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$44.06M 10-Q · filed 2024-08-08 | -$65.23M derived: sum of 3 quarters · filed 2024-08-08 | -$83.65M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$26.29M 10-Q · filed 2024-05-10 | -$47.45M derived: sum of 2 quarters · filed 2024-05-10 | -$65.87M derived: sum of 3 quarters · filed 2024-05-10 | -$84.91M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$21.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$39.58M derived: sum of 2 quarters · filed 2024-03-27 | -$58.62M derived: sum of 3 quarters · filed 2024-03-27 | -$67.60M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$18.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$37.45M derived: sum of 2 quarters · filed 2023-11-09 | -$46.43M 10-Q · filed 2023-11-09 | -$52.87M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$19.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$28.01M 10-Q · filed 2023-08-10 | -$34.45M derived: sum of 3 quarters · filed 2023-08-10 | -$39.94M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$8.98M 10-Q · filed 2023-05-11 | -$15.42M derived: sum of 2 quarters · filed 2023-05-11 | -$20.90M derived: sum of 3 quarters · filed 2023-05-11 | -$28.57M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$6.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$11.92M derived: sum of 2 quarters · filed 2023-03-28 | -$19.59M derived: sum of 3 quarters · filed 2023-03-28 | -$23.71M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$5.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$13.15M derived: sum of 2 quarters · filed 2022-11-09 | -$17.27M 10-Q · filed 2022-11-09 | -$44.65M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$7.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$11.79M 10-Q · filed 2022-08-10 | -$39.17M derived: sum of 3 quarters · filed 2022-08-10 | -$41.62M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$4.12M 10-Q · filed 2022-05-16 | -$31.50M derived: sum of 2 quarters · filed 2022-05-16 | -$33.95M derived: sum of 3 quarters · filed 2022-05-16 | -$36.63M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$27.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$29.83M derived: sum of 2 quarters · filed 2022-03-28 | -$32.50M derived: sum of 3 quarters · filed 2022-03-28 | -$34.81M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$5.12M derived: sum of 2 quarters · filed 2021-11-10 | -$7.43M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$4.98M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$2.31M 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |